文献速递肾血管病与高血压急性肾损伤慢性肾脏病

自体间充质干细胞输注治疗动脉粥样硬化性肾血管疾病的1a期剂量递增试验

In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.
PubMed 文献 · Kidney Int · 2019-12-13

三个月后,干细胞治疗组狭窄肾平均肾血流量从164增至190 ml/min,平均收缩压从144降至136 mmHg,平均双肾GFR(碘他拉酸)从53增至56 ml/min,且缺氧、肾静脉炎性细胞因子和血管生成生物标志物显著降低;对照组无此类变化。

要点

  • 自体间充质干细胞肾动脉输注可增加狭窄肾血流量和GFR,并降低血压。
  • 干细胞输注后肾静脉炎性细胞因子、血管生成标志物及缺氧显著降低。
  • 部分效应呈剂量依赖性,高剂量组GFR和血压变化最大。

核心结论

  • 自体间充质干细胞输注可增加动脉粥样硬化性肾血管疾病患者狭窄肾的血流和GFR,并减轻炎症损伤。

研究设计与样本

  • 两组在年龄、肾功能和血压上匹配,均接受相同研究方案,干细胞输注前及三个月后测量相关指标。

主要发现

  • 干细胞治疗组狭窄肾平均肾血流量从164增至190 ml/min。
  • 干细胞治疗组平均收缩压从144降至136 mmHg,平均双肾GFR(碘他拉酸)从53增至56 ml/min。
  • 干细胞输注后缺氧、肾静脉炎性细胞因子和血管生成生物标志物显著降低。
  • 高剂量干细胞治疗个体中GFR和血压变化最大,仅药物治疗组无此类变化。

临床怎么用

  • 对于动脉粥样硬化性肾血管疾病患者,自体间充质干细胞肾动脉输注可能作为增加肾血流、改善GFR和降低血压的潜在治疗选择。
  • 剂量依赖性效应提示未来可优化干细胞剂量以最大化疗效。

局限性

  • 为1a期小样本试验,需更大规模研究验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atherosclerotic renovascular disease (ARVD) reduces tissue perfusion and eventually leads to loss of kidney function with limited therapeutic options. Here we describe results of Phase 1a escalating dose clinical trial of autologous mesenchymal stem cell infusion for ARVD. Thirty-nine patients with ARVD were studied on two occasions separated by three months. Autologous adipose-derived mesenchymal stem cells were infused through the renal artery in 21 patients at three different dose levels (1, 2.5 and 5.0 × 105 cells/kg) in seven patients each. We measured renal blood flow, glomerular filtration rate (GFR) (iothalamate and estimated GFR), renal vein cytokine levels, blood pressure, and tissue oxygenation before and three months after stem cell delivery. These indices were compared to those of 18 patients with ARVD matched for age, kidney function and blood pressure receiving medical therapy alone that underwent an identical study protocol. Cultured mesenchymal stem cells were also studied in vitro. For the entire stem cell treated-cohort, mean renal blood flow in the treated stenotic kidney significantly increased after stem cell infusion from (164 to 190 ml/min). Hypoxia, renal vein inflammatory cytokines, and angiogenic biomarkers significantly decreased following stem cell infusion. Mean systolic blood pressure significantly fell (144 to 136 mmHg) and the mean two-kidney GFR (Iothalamate) modestly but significantly increased from (53 to 56 ml/min). Changes in GFR and blood pressure were largest in the high dose stem cell treated individuals. No such changes were observed in the cohort receiving medical treatment alone. Thus, our data demonstrate the potential for autologous mesenchymal stem cell to increase blood flow, GFR and attenuate inflammatory injury in post-stenotic kidneys. The observation that some effects are dose-dependent and related to in-vitro properties of mesenchymal stem cell may direct efforts to maximize potential therapeutic efficacy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Abumoawad A, Saad A, Ferguson CM, et al. In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure. Kidney Int. 2019. PMID: 32093917. doi:10.1016/j.kint.2019.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。